"These early results are intriguing," said Annick Desjardins, M.D., FRCPC, principal investigator and associate professor of medicine at Duke University School of Medicine.
"Current therapies for glioblastoma are limited because they cannot cross the blood-brain barrier and often do not specifically attack the tumor.
This treatment appears to overcome those problems.
We are eager to see additional results as we move forward with our study."
In addition to Desjardins
, study authors include J. H. Sampson, K.B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J.E. Herndon II, A. Friedman, H.S. Friedman, D.D. Bigner and M. Gromeier.